Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia

European Heart Journal

Volumn 37, Issue 39, 2016, Pages 2993-2997

  Marsch, Elke ^a   Demandt, Jasper A F ^a   Theelen, Thomas L ^a   Tullemans, Bibian M E ^a   Wouters, Kristiaan ^b   Boon, Mariëtte R ^c,d   Van Dijk, Theo H ^e   Gijbels, Marion J ^a,c,f   Dubois, Ludwig J ^a   Meex, Steven J R ^a   Mazzone, Massimiliano ^g,h   Hung, Gene ⁱ   Fisher, Edward A ^j   Biessen, Erik A L ^a,k   Daemen, Mat J A P ^f   Rensen, Patrick C N ^d   Carmeliet, Peter ^g,h   Groen, Albert K ^e   Sluimer, Judith C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ ISIS PHARMACEUTICALS   (United States)

^j NEW YORK UNIVERSITY   (United States)

^k RWTH AACHEN UNIVERSITY   (Germany)

more..

Author keywords

Atherosclerosis; Cholesterol and lipids; Hyperglycaemia; Inflammation; Oxygen sensor

Indexed keywords

GLUCOSE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; OXYGEN SENSOR PROLYL HYDROXYLASE 1; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; OXYGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD ANALYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIET INDUCED OBESITY; EXCRETION; FLOW CYTOMETRY; GLUCOSE INTOLERANCE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; LEUKOCYTE COUNT; MONOCYTE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; RECTUM HEMORRHAGE; ANIMAL; C57BL MOUSE; DISEASE MODEL; KNOCKOUT MOUSE;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXYGEN; PROLYL HYDROXYLASES; RECEPTORS, LDL;

EID: 84994336731     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw156     Document Type: Article

References (17)

1. NIH. Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents-NHLBI, NIH [Internet]. Report. 2012. http://www.nhlbi. nih.gov/health-pro/guidelines/current/cardiovascular-health-pediatricguidelines (16 January 2016
2. CDC. National Health Report:Leading causes of morbidity and mortality and associated behavioral risk and protective factors-United States, 2005-2013. MMWR 2014;63:3-27
3. Appelhoff RJ, Tian Y-M, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004;279:38458-38465
4. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54
5. Aragonés J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, Deroose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van Veldhoven P, Ratcliffe P, Baes M, Maxwell P, Carmeliet P. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet 2008;40:170-180
6. Moser SC, Bensaddek D, Ortmann B, Maure J-F, Mudie S, Blow JJ, Lamond AI, Swedlow JR, Rocha S. PHD1 links cell-cycle progression to oxygen sensing through hydroxylation of the centrosomal protein Cep192. Dev Cell 2013;26:381-392
7. The Jackson Laboratory. Which JAX mouse model is best for atherosclerosis studies:Apoe or Ldlr knockout mice? 2015. https://www.jax.org/news-Andinsights/jax-blog/2013/november/which-jax-mouse-model-is-best-foratherosclerosis-studies-Apoe-or-ldlr-knoc (27 February 2016
8. Selathurai A, Deswaerte V, Kanellakis P, Tipping P, Toh B-H, Bobik A, Kyaw T. Natural killer (NK) cells augment atherosclerosis by cytotoxic-dependent mechanisms. Cardiovasc Res 2014;102:128-137
9. Stewart FA, Heeneman S, Te Poele J, Kruse J, Russell NS, Gijbels M, Daemen M. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/-mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage. Am J Pathol 2006;168:649-658
10. Bakris GL, Yu K-HP, Leong R, Shi W, Lee T, Saikali K, Henry E, Neff TB. Late-breaking orals. J Clin Hypertens 2012;14:487-489
11. Olson E, Demopoulos L, Haws TF, Hu E, Fang Z, Mahar KM, Qin P, Lepore J, Bauer TA, Hiatt WR. Short-Term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc Med 2014;19:473-482
12. Rahtu-Korpela L, Karsikas S, HörkköS, Blanco Sequeiros R, Lammentausta E, MäkeläKA, Herzig K-H, Walkinshaw G, Kivirikko KI, Myllyharju J, Serpi R, Koivunen P. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes 2014;63:3324-3333
13. ClinicalTrials.gov. ClinicalTrials.gov-HIF-prolyl hydroxylase inhibitors in clinical trials. 2016. https://clinicaltrials.gov/ct2/results?term=prolyl+hydroxylase+CKD&Search=Search (16 January 2016
14. Holliger P, Prospero T, Winter G. 'Diabodies':Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993;90:6444-6448
15. Musallam KM, Porter JB, Sfeir PM, Tamim HM, Richards T, Lotta LA, Peyvandi F, Jamali FR. Raised haematocrit concentration and the risk of death and vascular complications after major surgery. Br J Surg 2013;100:1030-1036
16. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin:A meta-Analysis. Lancet 2007;369:381-388
17. van der Veen JN, van Dijk TH, Vrins CLJ, van Meer H, Havinga R, Bijsterveld K, Tietge UJF, Groen AK, Kuipers F. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J Biol Chem 2009;284:19211-19219